Performance of Lung Cancer Risk Prediction Models in Different Racial and Ethnic Groups in the United States: Results From the Lung Cancer Cohort Consortium
BACKGROUND: Racial and ethnic disparities are a concern in lung cancer screening. OBJECTIVE: To investigate the performance of risk prediction models to define screening eligibility across 4 U.S. racial and ethnic groups. DESIGN: Cohort study. SETTING: United States, Lung Cancer Cohort Consortium. PARTICIPANTS: 641 830 participants aged 50 to 80 years with a smoking history from 12 U.S. cohorts, including 6390 Asian, 9781 Hispanic, 39 872 non-Hispanic Black, and 585 787 non-Hispanic White participants. MEASUREMENTS: Calibration and discrimination were quantified for 16 lung cancer prediction models. Then, screening-related metrics were calculated after applying model thresholds to select the same number of eligible participants as the 2021 criteria from the U.S. Preventive Services Task Force (USPSTF-2021). These included eligibility, sensitivity, and efficiency measured as estimated number needed to screen (NNS; the ratio between participants and lung cancer cases) for each strategy or prediction model in each racial and ethnic group. RESULTS: General patterns across the 16 models included substantial underestimation of lung cancer risk in non-Hispanic Black participants (expected-observed ratio < 0.75 for 11 of 16 models), lower discrimination in Asian participants than all other groups (13 of 16 models), and lower discrimination in non-Hispanic Black than non-Hispanic White participants (15 of 16 models). When a same-sized screening-eligible population as USPSTF-2021 (38.0%) was enforced, all risk-based strategies achieved better average estimated screening efficiency and reduced racial and ethnic differences in efficiency compared with USPSTF-2021. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 (PLCOm2012) and Life Years gained From Screening-Computed Tomography model (LYFS-CT) performed best (mean estimated NNS, 36.5 [SD, 8.8] and 40.1 [SD, 8.2], respectively). However, no strategy could simultaneously optimize eligibility, sensitivity, and efficiency while also reducing racial and ethnic differences. LIMITATION: Smaller sample for Asian and Hispanic participants. CONCLUSION: To optimize efficiency and minimize its variation across racial and ethnic groups, risk-based strategies were superior to USPSTF criteria. Further optimization of prediction models for the diverse U.S. population is needed. PRIMARY FUNDING SOURCE: U.S. National Cancer Institute, Lung Cancer Research Foundation, and Cancer Research UK.
Authors
- Qiuyin Cai (ORCID: https://orcid.org/0000-0002-9384-5648)
- Alpa V. Patel (ORCID: https://orcid.org/0000-0001-9997-1218)
- Florence Guida (ORCID: https://orcid.org/0000-0002-9652-2430)
- Alan A. Arslan (ORCID: https://orcid.org/0000-0002-7775-8085)
- Linda M. Liao (ORCID: https://orcid.org/0000-0002-1923-5294)
- Xiaoshuang Feng (ORCID: https://orcid.org/0000-0002-7933-3996)
- Triplette Matthew
- Ying Wang (ORCID: https://orcid.org/0000-0001-6642-543X)
- Thomas E. Rohan (ORCID: https://orcid.org/0000-0001-6897-4045)
- Hilary A. Robbins (ORCID: https://orcid.org/0000-0001-6041-6866)
- Karine Alcala (ORCID: https://orcid.org/0000-0003-2308-9880)
- Xuehong Zhang (ORCID: https://orcid.org/0000-0002-8260-8508)
- Chu Chen (ORCID: https://orcid.org/0000-0003-2267-8050)
- Wei Zheng (ORCID: https://orcid.org/0000-0002-6957-7479)
- Aghiles Guenoun
- Howard D. Sesso
- Kala Visvanathan
- M C Aldrich
- Lesley F. Tinker
- Rashmi Sinha
- Mattias Johansson
Institutions
- Brigham and Women's Hospital (US)
- American Cancer Society (US)
- Albert Einstein College of Medicine (US)
- Johns Hopkins University (US)
- Yale University (US)
- Fred Hutch Cancer Center (US)
- Yale New Haven Health System (US)
- National Cancer Institute (US)
- Women's Health Initiative (US)
- Centre international de recherche sur le cancer (FR)
- New York University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Annals of Internal Medicine
- Published
- 2026-06-29
- DOI
- https://doi.org/10.7326/annals-25-03816
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- World Health Organization